Bevacizumab appears safe for neovascular AMD in short term

May 1, 2007

The short-term clinical experience with intravitreal bevacizumab (Avastin, Genentech) supports growing perception that treatment is safe and effective for neovascular age-related macular degeneration.

Related Content:

News